reference/30485649

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30485649

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	1287
issn	1520-4081 1522-7278
issueIdentifier	7
pageRange	1278-1287
publicationName	Environmental Toxicology
startingPage	1278
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ad0047d89326ce326fdce7923cf06c76 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b4a798caf2adb4871fe80ac408ae6d94 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_bc39e13c0051919fb96d73f6ddd70346
bibliographicCitation	Su C, Hsu T, Sung S, Huang M, Chen K, Huang C, Chiang CY, Su Y, Chen H, Liao P. AXL is crucial for E1A‐enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through NFI in breast cancer. Environmental Toxicology. 2021 Mar 18;36(7):1278–87. doi: 10.1002/tox.23125.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b0fbbe0d8f1ce23773f703ada15fbf9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_22d3fedab54c5dfa810d010346956392 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_783dbf4fb3d7603115c561dc4edad877 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0098e6be8221386cd8cf327824049d8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb5c537da9a1fdf51a6cc1ddb3922f00 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2347-0411 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5e1b3d9d7533d69790b3bebb2fb377a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0552c1a966a4dee310ec77b57b9228e3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4266-5428 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ecfdbca5693c4bddaab1edb66b4c979
date	2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/33734566 https://doi.org/10.1002/tox.23125
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22051 https://portal.issn.org/resource/ISSN/1522-7278 https://portal.issn.org/resource/ISSN/1520-4081
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	AXL is crucial for E1A‐enhanced therapeutic efficiency of EGFR tyrosine kinase inhibitors through NFI in breast cancer
discusses	http://id.nlm.nih.gov/mesh/M000756826 http://id.nlm.nih.gov/mesh/M0017909 http://id.nlm.nih.gov/mesh/M0328256 http://id.nlm.nih.gov/mesh/M0593322 http://id.nlm.nih.gov/mesh/M000756827 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0500817 http://id.nlm.nih.gov/mesh/M0124266
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000235 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D020794Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D011518Q000235 http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D047428Q000494 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D066246Q000235 http://id.nlm.nih.gov/mesh/D000094963 http://id.nlm.nih.gov/mesh/D051839 http://id.nlm.nih.gov/mesh/D019008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_84fb2c33ace7523546cbaab5d8570891 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a562d6cad6b682f0d1b38fc9ad70ae8e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_66f7ea23275c66ac400015028bcd7bcf http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_966b69495aff24dd4bc4208192414e49 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9cb7b36b3f2bccc776862e6f2f494077

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID558 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCNP_001690

Total number of triples: 63.